BridgeBio Pharma, Inc.
BBIO
$45.95
$1.142.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 235.81M | 127.42M | 221.90M | 217.77M | 219.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 235.81M | 127.42M | 221.90M | 217.77M | 219.12M |
| Cost of Revenue | 8.97M | 5.92M | 3.88M | 2.39M | 2.39M |
| Gross Profit | 226.84M | 121.50M | 218.02M | 215.37M | 216.73M |
| SG&A Expenses | 399.12M | 329.49M | 288.93M | 241.73M | 208.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 881.55M | 812.33M | 799.27M | 750.46M | 722.11M |
| Operating Income | -645.74M | -684.91M | -577.37M | -532.70M | -502.99M |
| Income Before Tax | -781.76M | -675.64M | -542.19M | -446.29M | -461.52M |
| Income Tax Expenses | 3.25M | 1.15M | 1.15M | -- | -- |
| Earnings from Continuing Operations | -785.01 | -676.80 | -543.35 | -446.29 | -461.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.59M | 8.83M | 7.59M | 7.43M | 7.70M |
| Net Income | -776.42M | -667.97M | -535.76M | -438.86M | -453.82M |
| EBIT | -645.74M | -684.91M | -577.37M | -532.70M | -502.99M |
| EBITDA | -640.23M | -679.15M | -571.29M | -526.40M | -496.59M |
| EPS Basic | -4.09 | -3.53 | -2.85 | -2.41 | -2.64 |
| Normalized Basic EPS | -2.60 | -2.67 | -2.24 | -2.06 | -2.02 |
| EPS Diluted | -4.09 | -3.53 | -2.85 | -2.41 | -2.64 |
| Normalized Diluted EPS | -2.60 | -2.67 | -2.24 | -2.06 | -2.02 |
| Average Basic Shares Outstanding | 758.61M | 755.68M | 744.24M | 729.26M | 704.06M |
| Average Diluted Shares Outstanding | 758.61M | 755.68M | 744.24M | 729.26M | 704.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |